Get started
Author

Sarala Rani Kayampeta

Observed names: Sarala R Kayampeta, Sarala R. Kayampeta
ORCID: 0009-0004-5279-4823
Observed ORCID: 0009-0004-5279-4823
OpenAlex ID: A5067960946
Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
2022 · Rajkumar Kulandaisamy, Tushar Kushwaha, et al. · Frontiers in Microbiology · 22
PDF
Redefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7
2025 · Deepa Singh, Tushar Kushwaha, et al. · Molecular Therapy — Nucleic Acids · 7
Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach
2023 · Aditya Trivedi, Vandana Kardam, et al. · FEBS Journal · 7
PDF
Psoralidin acts as a dual protease inhibitor against PL pro and M pro of SARS ‐ CoV ‐2
2025 · Aditya Trivedi, Tushar Kushwaha, et al. · FEBS Journal · 4
PDF
Author response for "Psoralidin acts as a dual protease inhibitor against PL pro and Mpro of SARS ‐ CoV ‐2"
2024 · Aditya Trivedi, Tushar Kushwaha, et al. · Publons reviews and discussion
Interaction of SCoV-2 NSP7 or NSP8 alone with NSP12 causes constriction of the RNA entry channel: Implications for novel RdRp inhibitor drug discovery
2023 · Deepa Singh, Tushar Kushwaha, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Author response for "Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico, biochemical, and cell‐based approach"
2023 · Aditya Trivedi, Vandana Kardam, et al. · Publons reviews and discussion
Works count: 7
Citation count: 40
H-index: 4
I10-index: 1
Year
Topic
Type